Are Heart-Lung Transplant Recipients Protected From Developing Bronchiolitis Obliterans Syndrome? Susan D. Moffatt-Bruce, MD, PhD, John Karamichalis, MD, Robert C. Robbins, MD, Richard I. Whyte, MD, James Theodore, MD, Bruce A. Reitz, MD The Annals of Thoracic Surgery Volume 81, Issue 1, Pages 286-291 (January 2006) DOI: 10.1016/j.athoracsur.2005.08.010 Copyright © 2006 The Society of Thoracic Surgeons Terms and Conditions
Fig 1 The incidence of cytomegalovirus (CMV) infection in heart-lung transplant (HLT; ♦) recipients was 58%, 59%, and 62% at 1, 3, and 5 years, respectively. The incidence of cytomegalovirus infection in the double-lung transplant (DLT; ■) recipients was significantly less at 45%, 47%, and 47% at 1, 3, and 5 years, respectively (p < 0.05). The Annals of Thoracic Surgery 2006 81, 286-291DOI: (10.1016/j.athoracsur.2005.08.010) Copyright © 2006 The Society of Thoracic Surgeons Terms and Conditions
Fig 2 The incidence of bronchiolitic obliterans syndrome (BOS) in the heart-lung transplant (HLT; ♦) recipients was 15%, 41%, and 48% at 1, 3, and 5 years, respectively. The incidence of bronchiolitic obliterans syndrome in the double-lung transplant (DLT; ■) recipients was 14%, 33%, and 46% at 1, 3, and 5 years, respectively. There was no statistically significant difference between these groups with respect to bronchiolitic obliterans syndrome. The Annals of Thoracic Surgery 2006 81, 286-291DOI: (10.1016/j.athoracsur.2005.08.010) Copyright © 2006 The Society of Thoracic Surgeons Terms and Conditions